Cardarine 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Usage

1. Confirm your goal is endurance enhancement or fat oxidation during a defined cut — Cardarine's PPARδ mechanism is most productive when aerobic output is consistently high.
2. Begin at one 10mg tablet per day, taken orally with water, ideally 30–60 minutes before aerobic training to align peak plasma exposure with workout demand.
3. Maintain the 10mg/day dose for the first two weeks to establish baseline tolerance; Cardarine's 16–24-hour half-life means plasma levels stabilize after approximately 4–5 days of consistent dosing.
4. If escalating to 20mg/day from week three, take both tablets as a single morning dose or split them AM and pre-workout — both approaches are consistent with the compound's half-life.
5. Support the fat-loss angle with a structured caloric deficit of 300–500 kcal/day and a cardio-prioritized training split to maximize substrate-utilization benefits of PPARδ activation.
6. Cap the cycle at 8 weeks; schedule bloodwork (lipid panel, liver enzymes) at cycle end regardless of stack composition, and allow a minimum 4-week off period before the next Cardarine cycle.

Warnings

Frequently asked questions

Why is Cardarine (GW-501516) not classified as a SARM?

Cardarine is not a SARM because it does not bind androgen receptors. It is a PPARδ agonist—a compound that selectively activates peroxisome proliferator-activated receptor delta, a nuclear receptor governing fat metabolism and mitochondrial gene expression. SARMs modulate androgen-responsive tissue; Cardarine modulates lipid oxidation and fiber-type gene transcription. The biological target, downstream pathway, and tissue selectivity are entirely different.

How does GW-501516 actually improve aerobic endurance capacity?

PPARδ activation by GW-501516 upregulates genes encoding enzymes for fatty-acid beta-oxidation and promotes the development of type I oxidative muscle fibers—the fiber type that resists fatigue during prolonged aerobic effort. This shifts substrate use toward fat at submaximal intensities, sparing glycogen stores and delaying onset of fatigue. Rodent model data show measurable increases in running distance, attributed to this fiber-type and metabolic shift rather than stimulant effects.

What dose of Cardarine do experienced users typically run during a cutting phase?

Research-aligned cutting protocols most frequently cite 10–20mg per day for 6–8 weeks. At 10mg daily—one tablet of this formulation—the PPARδ pathway is engaged with a conservative exposure suited to first-use cycles. Users targeting more aggressive fat oxidation support often escalate to 20mg (two tablets) from week three onward. Cycles beyond 8 weeks are not recommended given the duration-dependent nature of preclinical safety signals.

What makes the 10mg tablet strength a practical advantage over higher-concentration Cardarine formats?

The 10mg tablet is the most flexible unit in a Cardarine stack: it allows a precise start at 10mg/day with zero splitting, and a straightforward step-up to 20mg by adding a second tablet—no liquid measuring, no dose estimation. Higher-concentration tablets require splitting to achieve starter doses, which introduces dosing inconsistency. HPLC-verified potency at the tablet level means each 10mg unit is reliable as a standalone dose increment.

Does Cardarine (GW-501516) suppress natural testosterone production and require PCT?

Cardarine does not bind androgen receptors and does not suppress the hypothalamic-pituitary-gonadal (HPG) axis through androgenic signaling. PCT is therefore not required after a standalone Cardarine cycle. However, when Cardarine is stacked with anabolic or androgenic compounds—which do suppress endogenous testosterone—PCT protocols should follow based on those compounds, not Cardarine itself. Users should monitor bloodwork regardless of stack composition. (2) angle_used

Manufacturer

The production standard applied to Elbrus Pharmaceuticals' GW-501516 tablet line is built around one testable commitment: every tablet that leaves the facility carries documented evidence of its declared potency, not assumed equivalence to a raw material certificate. The pathway to that documentation begins at the brand's founding design principle — the quality chain for any oral research compound is only as strong as its weakest analytical checkpoint, and Elbrus treats the raw material intake stage and the finished-product release stage as two non-negotiable verification moments, not one. For this Cardarine formulation, GW-501516 API sourced from GMP-certified manufacturers is characterized for identity and purity before granulation begins; batches falling outside specification are rejected at intake rather than averaged into production. At the compression stage, tablet weight uniformity and content homogeneity targets are maintained under environmental conditions consistent with GMP-aligned facility standards, with shift-level production records retained for traceability. The released product undergoes finished-product HPLC analysis confirming that per-tablet GW-501516 content meets the declared 10mg specification within validated tolerance limits. The result is a batch record that connects API origin to finished-tablet potency in a traceable, auditable sequence — the kind of documentation that differentiates a manufactured compound from a compounded guess.